ADVANCING THE DIFFERENTIAL DIAGNOSIS OF HSIL AND LSIL IN PERIMENOPAUSE: A REVIEW OF MODERN OBJECTIVE CRITERIA
Abstract
Abstract: Cervical cancer remains a significant global health burden, ranking as the fourth most common malignancy among women worldwide, with approximately 660,000 new cases and 350,000 deaths reported in 2022. Despite advances in vaccination and screening, the disease disproportionately affects low- and middle-income countries, where incidence and mortality rates remain alarmingly high. Persistent infection with high-risk human papillomavirus (HPV) types, predominantly HPV 16 and 18, drives cervical carcinogenesis through the oncogenic actions of E6 and E7 proteins, which inactivate tumor suppressors p53 and pRb. The premenopausal period represents a particularly vulnerable window, during which hormonal fluctuations, immunological changes, and increased HPV susceptibility converge to elevate the risk of cervical intraepithelial neoplasia progression. This review synthesizes recent evidence on innovative diagnostic approaches for precancerous cervical lesions, with emphasis on integrated morphological, immunohistochemical, and nanoscale analytical methods. We examine the diagnostic utility of dual p16/Ki-67 immunostaining as a triage strategy for HPV-positive women, highlighting its superior sensitivity and specificity compared to conventional cytology. Emerging technologies including atomic force microscopy, scanning electron microscopy, and elemental tissue analysis are discussed as complementary tools for characterizing the biophysical and biochemical landscape of cervical dysplasia. The review further considers the role of DNA methylation markers, artificial intelligence-assisted diagnostics, and the incorporation of these modalities into risk stratification algorithms. Special attention is devoted to the clinical implications of these innovations for women in the premenopausal age group, where early detection and individualized management are critical for cancer prevention and fertility preservation.
References
1. Gisca T, Matasariu DR, Ursache A, et al. Integrating biomarkers into cervical cancer screening: advances in diagnosis and riskprediction. Diagnostics. 2025;15(24):3231.
2. Long B, Yang X, Bai Y. Latest updates on cervical cancer in 2025: a comprehensive review. Bali Med J. 2025;14(2):456-468.
3. Tillyashaykhov MN, et al. Cervical cancer epidemiology in Uzbekistan. Tashkent; 2017.
4. Zhou Q, Li T, Zhu L, et al. Clinical performance of cervical cancer screening strategies in premenopausal and postmenopausalwomen. Menopause. 2025;32(5):456-465.
5. Rosendo-Chalma P, Antonio-Vejar V, Ortiz Tejedor JG, et al. The hallmarks of cervical cancer: molecular mechanisms inducedby HPV. Biology. 2024;13(2):77.
6. Hamidi Sofiani V, Veisi P, Rezaei Zadeh Rukerd M, et al. The complexity of HPV in cancers: a narrative review. Infect AgentsCancer. 2023;18:13.
7. Baba SK, Alblooshi SSE, Yaqoob R, et al. HPV mediated cancers: an insightful update. J Transl Med. 2025;23:458.
8. Santoro A, Inzani F, Angelico G, et al. Recent advances in cervical cancer management: prognostic factors. Cancers.2023;15(4):1137.
9. Tung HJ, Schwarzschild G, Gopep NS, et al. Cervical cancer screening after menopause. Healthcare. 2025;13(10):1157.
10. Fitch KC, Bohn JA, Emerson J, et al. Acceptability of HPV self-collection and telehealth. Gynecol Oncol Rep. 2023;48:101226.
11. Trzeszcz M, Mazurec M, Jach R, et al. p16/Ki67 dual stain triage in primary HPV screening. J Med Virol. 2023;95(11):e29271.
12. Liu Y, Yang S, Ma Y, et al. HPV E6/E7 mRNA screening in premenopausal women. Int J Gynecol Obstet.2024;167(2):345-354.
13. Liu Y, Wen L, Jiang L, et al. p16, Ki-67, MCM2 in cervical lesion detection. Transl Cancer Res. 2025;14(5):1128-1140.
14. Clarke MA, Wentzensen N, Perkins RB, et al. Recommendations for p16/Ki67 dual stain use. J Low Genit Tract Dis.2024;28(2):103-113.
15. Chang Y, Li T, Zhou Q, et al. AI-assisted colposcopy in resource-limited populations. Obstet Gynecol Surv. 2026;81(1):23-30.
16. Ouh YT, Kim HY, Yi KW, et al. p16/Ki-67 dual staining review. Diagnostics. 2024;14(4):451.
17. Harper DM, Paczos T, Ridder R, et al. p16/Ki-67 dual stain triage for cervical precancer. Int J Cancer. 2025;156(3):542-553.
18. Ozbey G, Aytac S. Multimodal SEM-AFM for cervical cancer detection. Rev Assoc Med Bras. 2026;72:e20251173.
19. Waghe T, Acharya N. Advancements in CIN management: a review. Cureus. 2024;16(4):e58645.
20. Chen R, Zhang R, Zhang M, et al. HPV RNA location patterns and RNAscope for SIL. Diagn Pathol. 2023;18:23.
21. Stolnicu S, Allison D, Praiss A, et al. HPV-independent cervical SCC. Am J Surg Pathol. 2023;47(9):1023-1034.
22. Vallejo-Ruiz V, Gutierrez-Xicotencatl L, et al. Molecular aspects of cervical cancer pathogenesis. Front Oncol.2024;14:1356581.
23. Doorbar J. The papillomavirus life cycle. In: HPV and Cervical Cancer. Springer; 2023. p.1-24.
24. Fobian SF, Mei X, Crezee J, et al. HPV viral load correlated to cervical disease severity. J Med Virol. 2024;96(6):e29741.
25. Chaopotong P, Laiwejpithya S, Areeswate C. HR-HPV prevalence and vaccination. Asian Pac J Cancer Prev.2024;25(4):1241-1248.
26. Dura MC, Akturk H, Aslan O, et al. HPV prevalence in Turkey. Cureus. 2024;16(1):e52615.
27. An H, Ding L, Ma M, et al. Deep learning for cervical SIL recognition. Diagnostics. 2023;13(10):1720.
28. Li X, Chen Y, Xiong J, et al. Biomarkers for CIN2 regression vs progression. J Adv Res. 2024;9:009.
29. Luo H, Lian Y, Tao H, et al. p16/Ki67 immunoscore and methylation status. BMC Cancer. 2024;24:12920.
30. Harper DM, Anderson RJ, Baker E, et al. Cost-effectiveness of DS reflex. Cancer Prev Res. 2023;16(5):285-295.
31. Mazurec K, Trzeszcz M, Mazurec M, et al. HPV types and DS in post-colposcopy histology. Cancers. 2024;16(19):3401.
32. Hosseini M, Talayeh M, et al. Ki67 and P16 in cervical SIL. Caspian J Intern Med. 2023;14(1):69-77.
33. Ozono K, Kawakami F, Mikami Y. p16/Ki-67 IHC for HSIL diagnosis. Obstet Gynecol Sci. 2024;67(6):589-598.
34. von Knebel Doeberitz M. p16INK4a/Ki67 dual-staining for colposcopy triage. Acta Cytol. 2025;69(2):89-98.
35. Mazurec K, Trzeszcz M, Mazurec M, et al. Triage for non-16/18 HPV: DS vs cytology. Cancers. 2023;15(20):5095.
36. Huang Y, Feng L, Huang J, et al. E6/E7 mRNA, P16, Ki-67 for CIN2+/CIN3+. J Med Virol. 2025;97(5):e70405.
37. Sinha A, Chandra K, Sharma R, et al. p16 and Ki67 in cervical neoplasia. J Indira Gandhi Inst Med Sci. 2025;10(2):45-52.
38. Mehdi HK, Raju K, Sheela SR. P16, Ki-67, CD44 in HSIL and SCC. J Cancer Res Ther. 2023;19(1):112-119.
39. O'Dowling AT, Rodriguez BJ, Gallagher T, et al. ML and AI for AFM biomarkers. Comput Struct Biotechnol J.2024;23:3456-3467.
40. Proietti A, De Angelis E, Buccini L, et al. Raman, AFM, SEM of cervical cancer. PLoS One. 2026;21(1):e0327286.
41. Feng K, Yuan L, Zhang X. Adaptive harmonic AFM for cellular imaging. Appl Phys Lett. 2025;127(3):033701.
42. Medina-Ramirez IE, Macias-Diaz JE, et al. Holotomography and AFM for cancer. Discov Nano. 2024;19:56.
43. Qiu S, Wang Q, Jiang H, et al. Eag1 and p16/Ki-67 for CIN management. Diagn Pathol. 2024;19:95.
44. Popiel A, Grzegrzolka J, et al. Testin, Ki-67, p16 in cervical cancer. Curr Issues Mol Biol. 2023;45(1):32-45.
45. Sahin G, Yuksel Ulu F, et al. CIN II+ predictors in women over 65. BMC Geriatr. 2025;25:632.
46. Kong L, Sun W, Wu H, et al. DNA methylation triage for hrHPV women. Oncologist. 2024;29(12):e1789-e1798.
47. Lizano M, Carrillo-Garcia A, et al. Predictive biomarkers for cervical cancer. Int J Mol Med. 2024;54(1):57.
48. Endale HT, Mariye YF, et al. MiRNA in cervical cancer: systematic review. Heliyon. 2024;10(2):e24398.
49. Pisarska J, Kozanska A, et al. MicroRNA triage of HPV+ women. Cancers. 2026;18(4):559.
50. Jiang J, Li LB, Zhang C, et al. Liquid biopsy in cervical cancer. J Gynecol Oncol. 2025;36(1):e121.
51. Parvathy N, Gupta N. Screening in the molecular era. J Cytol. 2026;43(2):67-75.
52. Scott H, Kamraoui I, et al. Reference genes for dPCR in cervical precancer. J Virol Methods. 2025;332:115268.
53. Calfa S, de Freitas AJ, et al. miRNA in plasma, urine, LBC for CIN. Oncol Lett. 2025;30(6):492.
54. Ho SDK, Liu S, Lau LSK, et al. HPV in self-collected samples. J Low Genit Tract Dis. 2026;30(2):145-152.
55. Kubo-Kaneda M, Kondo E, et al. Endometrial LBC for ovarian cancer mutations. Oncol Lett. 2025;29(3):148.
56. Przybylski M, Pruski D, et al. E4 and L1 in SIL. Biomedicines. 2023;11(1):225.
57. Miranda-Falconi P, Flores-Pena G, et al. Molecular screening for cervical cancer in sera. Front Oncol. 2024;14:1483882.
58. Rodriguez-Nava C, Cortes-Sarabia K, et al. scFv for REST in premalignant lesions. Int J Mol Sci. 2025;26(24):11946.
59. Shanthini M, Grace Selvarani A. Multiplex biomarkers for cervical cancer. Proc IEEE ICICNIS. 2024.
60. Pesut E, Simic I, et al. Mass cytometry for cervical precancer. Cytometry B Clin Cytom. 2024;106(6):445-456.
61. Rosendo-Chalma P, et al. Molecular pathways of HPV-induced carcinogenesis. Biology. 2024.